- Home
- CCM vs RVPH Comparison
CCM vs RVPH Comparison
Compare CCM & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- RVPH
- Stock Information
- Founded
- CCM 1997
- RVPH 2006
- Country
- CCM China
- RVPH United States
- Employees
- CCM N/A
- RVPH N/A
- Industry
- CCM Medical/Nursing Services
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- CCM Health Care
- RVPH Health Care
- Exchange
- CCM Nasdaq
- RVPH Nasdaq
- Market Cap
- CCM 33.3M
- RVPH 32.8M
- IPO Year
- CCM 2009
- RVPH N/A
- Fundamental
- Price
- CCM $5.22
- RVPH $0.42
- Analyst Decision
- CCM
- RVPH Strong Buy
- Analyst Count
- CCM 0
- RVPH 5
- Target Price
- CCM N/A
- RVPH $9.00
- AVG Volume (30 Days)
- CCM 1.8K
- RVPH 3.4M
- Earning Date
- CCM 04-25-2025
- RVPH 08-13-2025
- Dividend Yield
- CCM N/A
- RVPH N/A
- EPS Growth
- CCM N/A
- RVPH N/A
- EPS
- CCM N/A
- RVPH N/A
- Revenue
- CCM $52,603,198.00
- RVPH N/A
- Revenue This Year
- CCM N/A
- RVPH N/A
- Revenue Next Year
- CCM N/A
- RVPH N/A
- P/E Ratio
- CCM N/A
- RVPH N/A
- Revenue Growth
- CCM N/A
- RVPH N/A
- 52 Week Low
- CCM $3.80
- RVPH $0.30
- 52 Week High
- CCM $10.50
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- CCM 33.93
- RVPH 33.44
- Support Level
- CCM $5.50
- RVPH $0.35
- Resistance Level
- CCM $5.68
- RVPH $0.83
- Average True Range (ATR)
- CCM 0.18
- RVPH 0.06
- MACD
- CCM 0.00
- RVPH -0.01
- Stochastic Oscillator
- CCM 21.79
- RVPH 17.36
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.